Health Authorities Clarify Insulin Availability Amid Shortage Claims

ISLAMABAD: Health authorities in Pakistan have dismissed reports of a widespread insulin shortage, clarifying that only one specific brand is currently unavailable due to international supply constraints. The announcement came on Tuesday following social media claims of a nationwide insulin deficit.

The health ministry, alongside the Drug Regulatory Authority of Pakistan (Drap), confirmed that while insulin glulisine (Apidra, Sanofi) is not available, alternative rapid-acting insulin analogues, such as insulin aspart (NovoRapid, Novo Nordisk) and insulin lispro (Humalog, Eli Lilly), are readily accessible across the country. Ministry spokesperson Sajid Shah emphasized that all other primary insulin classes remain fully stocked.

This clarification is crucial for patients who rely on insulin for diabetes management, as it alleviates concerns over medication access. The health ministry’s assurance aims to prevent panic among patients and ensure that they are informed about the available alternatives, which include various formulations of insulin analogues and human insulin.

Moving forward, health authorities are expected to monitor the situation closely and maintain communication with suppliers to ensure that the availability of insulin remains stable. Patients are encouraged to consult healthcare providers for guidance on alternative medications if needed.